- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
Authors
Keywords
-
Journal
Biomedicines
Volume 8, Issue 8, Pages 281
Publisher
MDPI AG
Online
2020-08-11
DOI
10.3390/biomedicines8080281
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metabolism of pancreatic cancer: paving the way to better anticancer strategies
- (2020) Cheng Qin et al. Molecular Cancer
- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
- (2020) Jenny Y. Xue et al. NATURE
- A genome-scale CRISPR screen identifies the ERBB and mTOR signalling networks as key determinants of response to PI3K inhibition in pancreatic cancer
- (2020) Charlotte K Milton et al. MOLECULAR CANCER THERAPEUTICS
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
- (2020) Irem Ozkan-Dagliyan et al. Cell Reports
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
- (2019) Tamer A. Ahmed et al. Cell Reports
- Targeting the untargetable KRAS in cancer therapy
- (2019) Pingyu Liu et al. Acta Pharmaceutica Sinica B
- Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
- (2019) Conan G. Kinsey et al. NATURE MEDICINE
- Genomic correlates of response to immune checkpoint blockade
- (2019) Tanya E. Keenan et al. NATURE MEDICINE
- Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
- (2019) Kirsten L. Bryant et al. NATURE MEDICINE
- Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF
- (2019) María Teresa Blasco et al. CANCER CELL
- Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
- (2019) Marwan Fakih et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
- (2019) Ryan J. Sullivan et al. NATURE MEDICINE
- Drugging an undruggable pocket on KRAS
- (2019) Dirk Kessler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions
- (2019) Maximilian Brunner et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition
- (2019) Meagan B. Ryan et al. CLINICAL CANCER RESEARCH
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
- (2019) G. Aaron Hobbs et al. Cancer Discovery
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers
- (2019) Tyler E. Mattox et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
- (2018) Eric Van Cutsem et al. INTERNATIONAL JOURNAL OF CANCER
- Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
- (2018) Anais Del Curatolo et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
- (2018) Gabrielle S. Wong et al. NATURE MEDICINE
- SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
- (2018) Leila Dardaei et al. NATURE MEDICINE
- The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
- (2018) Rasmus Hansen et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C
- (2018) Vincent L. Cannataro et al. ONCOGENE
- The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
- (2018) Rasmus Hansen et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Abstract 2375: Concurrent HER or PI3K inhibition potentiates the anti-tumor effect of ERK inhibitor BVD-523 (ulixertinib) in preclinical pancreatic cancer models
- (2018) Hongmei Jiang et al. CANCER RESEARCH
- Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer
- (2018) Nagaraj S Nagathihalli et al. CANCER RESEARCH
- Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes
- (2018) Sebastian Mueller et al. NATURE
- RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- (2018) Robert J. Nichols et al. NATURE CELL BIOLOGY
- SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
- (2018) Carmine Fedele et al. Cancer Discovery
- Current Approaches to Pancreatic Cancer Screening
- (2018) Ankit Chhoda et al. AMERICAN JOURNAL OF PATHOLOGY
- Targeted Therapies for Pancreatic Cancer and Hurdles Ahead
- (2018) MINELA ASLAN et al. ANTICANCER RESEARCH
- KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
- (2018) Angelina V. Vaseva et al. CANCER CELL
- KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
- (2018) Sandra Misale et al. CLINICAL CANCER RESEARCH
- Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)
- (2018) Sreenivasa Chandana et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Overcoming erlotinib resistance with STAT3 inhibition in pancreatic cancer.
- (2017) Matthew Philip Salzberg et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
- (2017) S-H Chen et al. ONCOGENE
- Molecular alterations contributing to pancreatic cancer chemoresistance
- (2017) Azam Rajabpour et al. PANCREATOLOGY
- Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters
- (2017) Patricia Dauer et al. PANCREATOLOGY
- KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
- (2017) Andrew M. Waters et al. Cold Spring Harbor Perspectives in Medicine
- Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It’s Down
- (2016) G. Aaron Hobbs et al. CANCER CELL
- Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
- (2016) Tikvah K. Hayes et al. CANCER CELL
- Critical role of oncogenic KRAS in pancreatic cancer (Review)
- (2016) JIANG LIU et al. Molecular Medicine Reports
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- (2016) Ying-Nan P. Chen et al. NATURE
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma
- (2016) Matthew H. Wong et al. NEOPLASIA
- Gemcitabine resistance in pancreatic ductal adenocarcinoma
- (2015) Yoav Binenbaum et al. DRUG RESISTANCE UPDATES
- Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer
- (2015) Nagaraj S. Nagathihalli et al. GASTROENTEROLOGY
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
- (2015) J. C. Hunter et al. MOLECULAR CANCER RESEARCH
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices
- (2015) Elizaveta S. Leshchiner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
- (2015) Talia Golan et al. Oncotarget
- Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy
- (2015) Hayato Fujita et al. NEOPLASIA
- Oncogenic KRAS signalling in pancreatic cancer
- (2014) S Eser et al. BRITISH JOURNAL OF CANCER
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
- (2014) Avnish Kapoor et al. CELL
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
- (2014) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs
- (2014) C. V. Pecot et al. MOLECULAR CANCER THERAPEUTICS
- Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
- (2014) Andrea Viale et al. NATURE
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Small RNA combination therapy for lung cancer
- (2014) W. Xue et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development of siRNA Payloads to Target KRAS-Mutant Cancer
- (2014) T. L. Yuan et al. Cancer Discovery
- KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
- (2013) Stefan Boeck et al. JOURNAL OF GASTROENTEROLOGY
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- (2013) Georgia Hatzivassiliou et al. NATURE
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation
- (2012) Qi Sun et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
- (2012) A. Gonçalves et al. ANNALS OF ONCOLOGY
- EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
- (2012) Christine M. Ardito et al. CANCER CELL
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
- (2012) Haoqiang Ying et al. CELL
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients
- (2012) Mengmeng Yang et al. INTERNATIONAL JOURNAL OF CANCER
- ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
- (2012) G. Hatzivassiliou et al. MOLECULAR CANCER THERAPEUTICS
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells
- (2011) C. H. Diep et al. CLINICAL CANCER RESEARCH
- Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology
- (2011) Pawel K Mazur et al. GUT
- An orthosteric inhibitor of the Ras-Sos interaction
- (2011) Anupam Patgiri et al. Nature Chemical Biology
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epidemiology of pancreatic cancer in Norway: trends in incidence, basis of diagnosis and survival 1965–2007
- (2009) Kjetil Søreide et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins
- (2008) B. B. Friday et al. CANCER RESEARCH
- Current Adjuvant and Targeted Therapies for Pancreatic Adenocarcinoma
- (2008) Sabrina Sanchez et al. CURRENT MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started